Pravastatin potentiates the anticoagulant effects of low molecular weight heparin

Thrombosis Research
Jennifer E ZimmerRohit R Arora

Abstract

Statins have been shown in randomized trials to reduce coronary events independent of baseline LDL-C level. In the case of pravastatin sodium (PS), there is conflicting evidence as to what is the actual mechanism of its non-lipid lowering beneficial effects. Because pravastatin has been found to prolong the clotting time in vitro, we conducted a study to determine if pravastatin plus low molecular weight heparin (LMWH) would result in a synergistic effect on the in vitro clotting time, thus supporting the hypothesis that pravastatin exerts antithrombotic effects through reduction of fibrin formation. Aliquots of PS were combined with dalteparin, a LMWH, in 500 microl of human whole blood. The clotting time in seconds was analyzed on a Sonoclot Coagulation Analyzer, a miniviscometer that is sensitive to early fibrin generation. PS and LMWH, each resulted in a significant prolongation of the clotting time compared with control. The combination of PS and LMWH resulted in a significantly prolonged clotting time compared with either given alone. All values were significantly different from each other (p<0.05). Our results showed that the combination of PS and a LMWH prolongs the clotting time to a significantly greater degree when c...Continue Reading

Citations

Feb 11, 2021·BioMed Research International·Antonio NennaMassimo Chello
Jun 29, 2021·Thrombosis Journal·Mohammadreza BordbarWillem M Lijfering

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.